Results 171 to 180 of about 5,796 (217)
Some of the next articles are maybe not open access.
Improving the prescribing of palivizumab
Journal of Paediatrics and Child Health, 2018AimPalivizumab prevents respiratory syncytial virus (RSV) in children at high risk of severe disease. This paper reviews the use and effectiveness of palivizumab at two tertiary paediatric hospitals (hospitals A and B) in New South Wales, Australia.MethodsChildren prescribed palivizumab during the pre‐intervention period, 1 January 2013 until 31 ...
Simone Trist +4 more
openaire +2 more sources
Hospital Medicine, 1999
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if ...
openaire +2 more sources
Optimum Dosage Regimen of Palivizumab?
Therapeutic Drug Monitoring, 2002Palivizumab is a humanized, monoclonal antibody used to protect at-risk infants against respiratory syncytial virus (RSV) infection. The regular dosage scheme causes a low initial trough level and accumulation of the antibody after subsequent injections.
Zaaijer, Hans L. +2 more
openaire +3 more sources
Palivizumab prophylaxis in ‘late preterm’ newborns
The Journal of Maternal-Fetal & Neonatal Medicine, 2010In the last decades the preterm birth rate rose more than 20%, largely because of an increase among deliveries of 'late preterm' infants, i.e. those born at 34 to 36 weeks gestational age. Late preterm infants are more susceptible to infection by pathogens, such as respiratory syncytial virus (RSV), possibly because of the immaturity of both the ...
LANARI, MARCELLO +2 more
openaire +3 more sources
Cost–effectiveness of palivizumab in infancy
Expert Review of Pharmacoeconomics & Outcomes Research, 2007Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to reduce hospitalizations in infected ...
Nicholas D, Embleton +2 more
openaire +2 more sources
Pediatric Infectious Disease Journal, 2015
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in infants. Palivizumab, a means of passive prophylaxis, relies on patient adherence to ensure therapeutic effectiveness. The objective of this study is to evaluate the association between adherence and the incidence of RSV-associated outcomes and to identify ...
Parco, Chan +5 more
openaire +2 more sources
Administration of Palivizumab in the NICU
Hospital Pediatrics, 2016BACKGROUND: The American Academy of Pediatrics recommends palivizumab prophylaxis against respiratory syncytial virus (RSV) for infants at high risk for severe disease within 72 hours of hospital discharge to prevent community-associated RSV.
Neika, Vendetti +5 more
openaire +2 more sources
Questions About Palivizumab (Synagis)
Pediatrics, 1999To the Editor. A humanized monoclonal antibody designed for the prevention of serious disease attributable to respiratory syncytial virus (RSV) has recently been approved by the Food and Drug Administration (FDA). Palivizumab, manufactured by MedImmune, Inc (Gaithersburg, MD) and marketed as Synagis, is indicated for pediatric patients who are at ...
openaire +1 more source
Palivizumab (Synagis): Counting “Costs” and Values
Pediatrics, 2000To the Editor. The continuing reports, letters, and pharmacoeconomic analyses concerning the use of expensive respiratory syncytial virus (RSV) prophylaxis regimens for neonatal intensive care unit (NICU) graduates mark what appears to be a shift in decisional processes for clinicians.1–3 The consideration of cost, although not new in medical or ...
openaire +2 more sources